Security
LGNXZ · LIGAND PHARMACEUTICALS INC
LGNXZOTCRightCurrentCIK 886163Updated Sep 24, 2026
Name history
LIGAND PHARMACEUTICALS · through Sep 13, 1994
LGNXZ price & chart
Derivative provider spelling needs an explicit mapping.
About the company
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01
Regulation FD Disclosure
Items 7.01, 9.01
144 filing
144 filing
Financial Statements and Exhibits
Items 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,560,637,000Source | 941,774,000Source | 787,216,000Source | 762,668,000Source |
| Property, Plant and Equipment, NetUSD | 3,571,000Source | 15,133,000Source | 15,607,000Source | 12,482,000Source |
| GoodwillUSD | 101,541,000Source | 105,250,000Source | 103,370,000Source | 105,673,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 225,438,000Source | 266,648,000Source | 299,606,000Source | 342,455,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 174,927,000Source | 72,307,000Source | 22,954,000Source | 45,006,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 59,601,000Source | 38,376,000Source | 32,917,000Source | 30,424,000Source |
| Inventory, NetUSD | 9,126,000Source | 14,114,000Source | 23,969,000Source | 13,294,000Source |
| Assets, CurrentUSD | 832,271,000Source | 331,559,000Source | 237,429,000Source | 263,601,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,152,000Source | 6,907,000Source | 6,062,000Source | 10,914,000Source |
| Other Assets, NoncurrentUSD | 12,582,000Source | 6,924,000Source | 5,923,000Source | 4,736,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 543,425,000Source | 111,335,000Source | 86,303,000Source | 165,183,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 20,000Source | 20,000Source | 18,000Source | 17,000Source |
| Additional Paid in CapitalUSD | 400,649,000Source | 337,377,000Source | 198,696,000Source | 147,590,000Source |
| Retained Earnings (Accumulated Deficit)USD | 608,088,000Source | 498,984,000Source | 503,016,000Source | 450,862,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 8,455,000Source | -5,942,000Source | -817,000Source | -984,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,017,212,000Source | 830,439,000Source | 700,913,000Source | 597,485,000Source |
| Liabilities and EquityUSD | 1,560,637,000Source | 941,774,000Source | 787,216,000Source | 762,668,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 37,447,000Source | 37,112,000Source | 16,782,000Source | 98,810,000Source |
| Operating Lease, Liability, CurrentUSD | 1,095,000Source | 1,266,000Source | 403,000Source | 670,000Source |
| Accounts Payable, CurrentUSD | 3,238,000Source | 5,233,000Source | 2,427,000Source | 5,307,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,204,000Source | 5,815,000Source | 5,755,000Source | 10,336,000Source |
| Deferred Income Tax Liabilities, NetUSD | 36,019,000Source | 32,524,000Source | 31,622,000Source | 30,615,000Source |
| Other Liabilities, NoncurrentUSD | 16,629,000Source | 30,163,000Source | 27,758,000Source | 21,966,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 31,453,000Source | 27,906,000Source | 12,467,000Source | 15,681,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | 1,444,000Source | — |
| Deferred Tax Liabilities, NetUSD | 27,674,000Source | 32,452,000Source | 31,408,000Source | 22,085,000Source |
| Short-term InvestmentsUSD | 558,594,000Source | 183,858,000Source | 147,355,000Source | 166,864,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -33,361,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 33,775,000Source | 35,239,000Source | 36,521,000Source | 51,534,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 46,849,000Source | 41,089,000Source | 25,743,000Source | 60,285,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 21,737,000Source | 6,459,000Source | 2,601,000Source | -55,319,000Source |
| Increase (Decrease) in InventoriesUSD | -4,988,000Source | -9,619,000Source | 10,870,000Source | -12,058,000Source |
| Deferred Income Tax Expense (Benefit)USD | 21,890,000Source | -15,800,000Source | 10,029,000Source | 30,488,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 49,359,000Source | 97,047,000Source | 49,577,000Source | 137,850,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | 0Source | 10,405,000Source | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -377,322,000Source | -143,664,000Source | -11,682,000Source | 163,624,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | 0Source | 0Source | 960,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 452,000Source | 1,821,000Source | 3,521,000Source | 17,923,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 9,599,000Source | 5,136,000Source | 4,547,000Source | 8,236,000Source |
| Payments for Repurchase of Common StockUSD | 15,000,000Source | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 428,223,000Source | 97,141,000Source | -59,947,000Source | -275,990,000Source |
| Repayments of Long-term DebtUSD | 0Source | 0Source | 76,854,000Source | 260,949,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 102,620,000Source | 49,353,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 174,927,000Source | 72,307,000Source | 22,954,000Source | 45,006,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 321,000Source | 263,000Source | 288,000Source | 1,428,000Source |
| Income Taxes Paid, NetUSD | 7,802,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,360,000Source | -1,171,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Debt Issuance Costs and DiscountsUSD | 1,273,000Source | 486,000Source | 240,000Source | 734,000Source |
| DepreciationUSD | 1,000,000Source | 2,300,000Source | 2,900,000Source | 3,800,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | 0Source | -15,055,000Source | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 90,670,000Source | -25,788,000Source | — | — |
| Gain (Loss) on InvestmentsUSD | 18,433,000Source | 75,024,000Source | 46,365,000Source | 28,540,000Source |
| Gain (Loss) on Disposition of BusinessUSD | 0Source | 0Source | 2,121,000Source | 0Source |
| Gain (Loss) on Sale of DerivativesUSD | — | — | 300,000Source | — |
| Gain (Loss) on Disposition of Other AssetsUSD | 53,072,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | 0Source | 4,192,000Source |
| General and Administrative ExpenseUSD | 92,449,000Source | 78,654,000Source | 52,790,000Source | 70,062,000Source |
| GoodwillUSD | 101,541,000Source | 105,250,000Source | 103,370,000Source | 105,673,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | 0Source | 0Source | 0Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 6,197,000Source | 30,572,000Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | 124,453,000Source | -4,032,000Source | 53,819,000Source | -5,219,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | -1,665,000Source | -28,142,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | -12,821,000Source | -1,829,000Source | — |
| Income Tax Expense (Benefit)USD | 34,507,000Source | 6,550,000Source | 9,841,000Source | 41,230,000Source |
| InterestExpenseNonoperatingUSD | 4,715,000Source | 3,037,000Source | — | — |
| Inventory Write-downUSD | 0Source | 200,000Source | 200,000Source | 1,100,000Source |
| Investment Income, InterestUSD | 13,659,000Source | 8,055,000Source | 7,711,000Source | 2,046,000Source |
| Net Income (Loss) Attributable to ParentUSD | 124,453,000Source | -4,032,000Source | 52,154,000Source | -33,361,000Source |
| Nonoperating Income (Expense)USD | 117,958,000Source | 25,124,000Source | 51,718,000Source | 32,974,000Source |
| Operating Costs and ExpensesUSD | 227,085,000Source | 189,739,000Source | 121,493,000Source | 193,208,000Source |
| Operating Lease, ExpenseUSD | 900,000Source | 1,300,000Source | 1,400,000Source | 700,000Source |
| Other Nonoperating Income (Expense)USD | -89,000Source | -54,918,000Source | -1,952,000Source | 4,187,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 0Source | 0Source |
| Payments for Repurchase of WarrantsUSD | — | — | 0Source | 0Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 37,140,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 47,501,000Source | 65,588,000Source | 22,448,000Source | 3,232,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | 1,022,000Source | -20,010,000Source | 250,000Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 181,000Source | 45,000Source | 212,000Source | -85,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 268,087,000Source | 167,133,000Source | 131,314,000Source | 196,245,000Source |
| Operating Income (Loss)USD | 41,002,000Source | -22,606,000Source | 11,942,000Source | 3,037,000Source |
| Other Nonoperating Income (Expense)USD | -89,000Source | -54,918,000Source | -1,952,000Source | 4,187,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 158,960,000Source | 2,518,000Source | 63,660,000Source | 36,011,000Source |
| Income Tax Expense (Benefit)USD | 34,507,000Source | 6,550,000Source | 9,841,000Source | 41,230,000Source |
| Net Income (Loss) Attributable to ParentUSD | 124,453,000Source | -4,032,000Source | 52,154,000Source | -33,361,000Source |
| Earnings Per Share, BasicUSD per share | 6.44Source | -0.22Source | 3.02Source | -1.98Source |
| Earnings Per Share, DilutedUSD per share | 6.13Source | -0.22Source | 2.94Source | -1.98Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 19,338,000Source | 18,290,000Source | 17,298,000Source | 16,868,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 20,294,000Source | 18,290,000Source | 17,757,000Source | 16,868,000Source |
| Interest Expense (non-operating)USD | 4,715,000Source | 3,037,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 12,617,000Source | 22,350,000Source | -188,000Source | 10,742,000Source |
| Gain (Loss) on InvestmentsUSD | 18,433,000Source | 75,024,000Source | 46,365,000Source | 28,540,000Source |
| General and Administrative ExpenseUSD | 92,449,000Source | 78,654,000Source | 52,790,000Source | 70,062,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | 124,453,000Source | -4,032,000Source | 53,819,000Source | -5,219,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 126,428,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | 6.44Source | -0.22Source | 3.11Source | -0.31Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | 6.13Source | -0.22Source | 3.03Source | -0.31Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | -1,665,000Source | -28,142,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | -12,821,000Source | -1,829,000Source | — |
| Interest ExpenseUSD | — | — | 656,000Source | 1,799,000Source |
| Investment Income, InterestUSD | 13,659,000Source | 8,055,000Source | 7,711,000Source | 2,046,000Source |
| Nonoperating Income (Expense)USD | 117,958,000Source | 25,124,000Source | 51,718,000Source | 32,974,000Source |
| Operating Costs and ExpensesUSD | 227,085,000Source | 189,739,000Source | 121,493,000Source | 193,208,000Source |
| Operating Lease, ExpenseUSD | 900,000Source | 1,300,000Source | 1,400,000Source | 700,000Source |
| Other Operating Income (Expense), NetUSD | — | — | 0Source | 0Source |
| Research and Development ExpenseUSD | 81,182,000Source | 21,425,000Source | 24,537,000Source | 36,082,000Source |
Filing attachments
q22026earningsrelease_ex991.htm · 8-K · 2026-08-06
EX-99.1 2 q22026earningsrelease_ex991.htm EX-99.1 Document Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., August 6, 2026 - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 20…
Read attachment ↗d108457dex991.htm · 8-K · 2026-07-14
EX-99.1 2 d108457dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets Acquisition adds seven commercial products including VABYSMO ® (faricimab-svoa), OJEMDA ™ (tovorafenib), and MIPLYFFA ® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Inve…
Read attachment ↗d167360dex41.htm · 8-K · 2026-06-25
EX-4.1 2 d167360dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 LIGAND PHARMACEUTICALS INCORPORATED AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 25, 2026 0.00% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page ARTICLE 1 Definitions Section 1.01. Definitions …
Read attachment ↗d167360dex991.htm · 8-K · 2026-06-25
EX-99.1 5 d167360dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes ───────────────────────────────────────────────────────────────────────…
Read attachment ↗d167360dex992.htm · 8-K · 2026-06-25
EX-99.2 6 d167360dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Ligand Announces Closing of Convertible Senior Notes Offering Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes ────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗d41408dex991.htm · 8-K · 2026-06-22
EX-99.1 3 d41408dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031 Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes ───────────────────────────────────────────────────────────────────…
Read attachment ↗